X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Goat Anti-Rabbit IgG (H+L) Highly Cross-adsorbed Antibody, Alexa Fluor ?? 633 Conjugated

RRID:AB_141419

Antibody ID

AB_141419

Target Antigen

Rabbit IgG (H+L) rabbit

Vendor

Molecular Probes

Cat Num

A-21071 also A21071

Proper Citation

(Molecular Probes Cat# A-21071, RRID:AB_141419)

Clonality

unknown

Host Organism

goat

Comments

discontinued at Molecular Probes please see Thermo Fisher for the same product; This product offered by Molecular Probes (Invitrogen), now part of Thermo Fisher:

Publications that use this research resource

Fragile X Mental Retardation Protein Restricts Small Dye Iontophoresis Entry into Central Neurons.

  • Kennedy T
  • J. Neurosci.
  • 2017 Oct 11

Literature context: bbit (1:250; Life Technologies, RRID:AB_141419). Neurobiotin was labeled with


Abstract:

Fragile X mental retardation protein (FMRP) loss causes Fragile X syndrome (FXS), a major disorder characterized by autism, intellectual disability, hyperactivity, and seizures. FMRP is both an RNA- and channel-binding regulator, with critical roles in neural circuit formation and function. However, it remains unclear how these FMRP activities relate to each other and how dysfunction in their absence underlies FXS neurological symptoms. In testing circuit level defects in the Drosophila FXS model, we discovered a completely unexpected and highly robust neuronal dye iontophoresis phenotype in the well mapped giant fiber (GF) circuit. Controlled dye injection into the GF interneuron results in a dramatic increase in dye uptake in neurons lacking FMRP. Transgenic wild-type FMRP reintroduction rescues the mutant defect, demonstrating a specific FMRP requirement. This phenotype affects only small dyes, but is independent of dye charge polarity. Surprisingly, the elevated dye iontophoresis persists in shaking B mutants that eliminate gap junctions and dye coupling among GF circuit neurons. We therefore used a wide range of manipulations to investigate the dye uptake defect, including timed injection series, pharmacology and ion replacement, and optogenetic activity studies. The results show that FMRP strongly limits the rate of dye entry via a cytosolic mechanism. This study reveals an unexpected new phenotype in a physical property of central neurons lacking FMRP that could underlie aspects of FXS disruption of neural function.SIGNIFICANCE STATEMENT FXS is a leading heritable cause of intellectual disability and autism spectrum disorders. Although researchers established the causal link with FMRP loss >;25 years ago, studies continue to reveal diverse FMRP functions. The Drosophila FXS model is key to discovering new FMRP roles, because of its genetic malleability and individually identified neuron maps. Taking advantage of a well characterized Drosophila neural circuit, we discovered that neurons lacking FMRP take up dramatically more current-injected small dye. After examining many neuronal properties, we determined that this dye defect is cytoplasmic and occurs due to a highly elevated dye iontophoresis rate. We also report several new factors affecting neuron dye uptake. Understanding how FMRP regulates iontophoresis should reveal new molecular factors underpinning FXS dysfunction.

Funding information:
  • Biotechnology and Biological Sciences Research Council - BB/F017464/1(United Kingdom)
  • NICHD NIH HHS - T32 HD007502()
  • NICHD NIH HHS - U54 HD083211()
  • NIMH NIH HHS - R01 MH084989()
  • NINDS NIH HHS - F31 NS092250()

Gli1+ Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target.

  • Schneider RK
  • Cell Stem Cell
  • 2017 Jun 1

Literature context: A-21071, RRID:AB_141419 Bacterial


Abstract:

Bone marrow fibrosis (BMF) develops in various hematological and non-hematological conditions and is a central pathological feature of myelofibrosis. Effective cell-targeted therapeutics are needed, but the cellular origin of BMF remains elusive. Here, we show using genetic fate tracing in two murine models of BMF that Gli1+ mesenchymal stromal cells (MSCs) are recruited from the endosteal and perivascular niche to become fibrosis-driving myofibroblasts in the bone marrow. Genetic ablation of Gli1+ cells abolished BMF and rescued bone marrow failure. Pharmacological targeting of Gli proteins with GANT61 inhibited Gli1+ cell expansion and myofibroblast differentiation and attenuated fibrosis severity. The same pathway is also active in human BMF, and Gli1 expression in BMF significantly correlates with the severity of the disease. In addition, GANT61 treatment reduced the myofibroblastic phenotype of human MSCs isolated from patients with BMF, suggesting that targeting of Gli proteins could be a relevant therapeutic strategy.